EIKN
Eikon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.39
+15.14%Institutional positioning
13F filings over the trailing two quarters
New 47Increased 19Reduced 11Sold out 18
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 4,993,906 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 4,281,425 | Aug 7, 2026 |
| Foresite Capital Management IV, LLC | Unchanged | 1,943,682 | Aug 14, 2026 |
| Merck & Co., Inc. | Unchanged | 1,666,666 | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | Increased | 1,595,274 | Aug 14, 2026 |
| Foresite Capital Management V, LLC | Unchanged | 1,318,983 | Aug 14, 2026 |
| Capital World Investors | Increased | 1,175,944 | Aug 12, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 1,005,035 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 969,431 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 922,707 | Aug 13, 2026 |
| EcoR1 Capital, LLC | Unchanged | 732,606 | Aug 14, 2026 |
| ALLIANCEBERNSTEIN L.P. | Reduced | 641,888 | Aug 14, 2026 |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | New Position | 635,131 | Oct 26, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 556,955 | Aug 12, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 555,555 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings